Endonovo Therapeutics (ENDV) Other Gross PP&E Adjustments (2016 - 2022)
Endonovo Therapeutics has reported Other Gross PP&E Adjustments over the past 10 years, most recently at -$646910.0 for Q3 2022.
- Quarterly results put Other Gross PP&E Adjustments at -$646910.0 for Q3 2022, down 820.44% from a year ago — trailing twelve months through Jun 2023 was -$646910.0 (up 50.0% YoY), and the annual figure for FY2020 was $89794.0, changed 0.0%.
- Other Gross PP&E Adjustments for Q3 2022 was -$646910.0 at Endonovo Therapeutics, roughly flat from -$646910.0 in the prior quarter.
- Over the last five years, Other Gross PP&E Adjustments for ENDV hit a ceiling of $89795.0 in Q3 2019 and a floor of -$646910.0 in Q1 2022.
- Median Other Gross PP&E Adjustments over the past 5 years was $89433.0 (2019), compared with a mean of -$33750.3.
- Biggest five-year swings in Other Gross PP&E Adjustments: grew 2.97% in 2019 and later tumbled 820.44% in 2022.
- Endonovo Therapeutics' Other Gross PP&E Adjustments stood at $87201.0 in 2018, then increased by 2.97% to $89794.0 in 2019, then changed by 0.0% to $89794.0 in 2020, then changed by 0.0% to $89794.0 in 2021, then tumbled by 820.44% to -$646910.0 in 2022.
- The last three reported values for Other Gross PP&E Adjustments were -$646910.0 (Q3 2022), -$646910.0 (Q2 2022), and -$646910.0 (Q1 2022) per Business Quant data.